Market Trends of Thyroid Eye Disease Treatment Industry
This section covers the major market trends shaping the Thyroid Eye Disease Treatment Market according to our research experts:
Monoclonal Antibody Segment Expected to Witness Growth over the Forecast Period
The monoclonal antibodies (mAbs), cloned from antibodies produced in the body, are used to treat many fatal diseases. The main advantage of using monoclonal antibodies in treating these diseases is that they are taken from a biological source and can produce antibodies in the long term. Monoclonal antibodies are types of proteins that are made in labs. They can bind to a specific target in the body, such as antigens and the surface of cells.
mAbs assist in fighting against various infections and are given to the patients directly as infusions. For instance, Tocilizumab, an FDA-approved monoclonal antibody, works by blocking the antibodies from attacking the orbit and is increasingly used to treat thyroid eye disease. Hence, due to the beneficial treatment options provided by the drug, it is becoming more popular among patients suffering from thyroid eye disease, ultimately driving market growth.
Furthermore, in May 2021, the NCBI stated that monoclonal antibodies, such as Tocilizumab, work against the interleukin 6 receptor. Tocilizumab blocks the antibodies from attacking the fibroblasts, prevents muscle and sat tissue remodeling, and halts hyaluronan buildup in orbit. Tocilizumab improved 93% of the patients at 16 weeks, with minimal proptosis. Hence, the monoclonal antibody segment is going to keep growing.
Therefore, the monoclonal antibody segment is expected to witness significant growth over the forecast period.
North America Expected to Dominate the Market
Owing to significant factors, such as the increasing prevalence of various thyroid diseases in the United States and advancement toward new treatment options, North America is expected to dominate the market.
According to the American Academy of Ophthalmology data published in July 2022, around 19 in 100,000 people suffer from thyroid eye disease in the United States. Thus, the prevalence of thyroid eye disease in the United States will promote the growth of the market studied in the region.
Key product launches, the high concentration of market players, and the manufacturers' presence in the United States are some factors driving the growth of the ortho-pediatric devices market. For instance, in January 2020, Horizon Therapeutics PLC announced the approval of TEPEZZA for treating thyroid eye disease by the Food and Drug Administration. Such continuous regional collaborations are anticipated to drive market growth in the country.
Therefore, owing to the aforementioned factors, the market's growth is anticipated in North America.
